Ministero della Salute

The potential of Personalised Medicine (PM) is to improve prevention, diagnosis and treatment of diseases by taking into account individuals' genotypes and phenotypes as well as other biomedical, life style and environmental data. In the last decade, significant advancements have been made especially for cancer or rare diseases. However, due to fragmentation and high upfront-investments the implementation of PM remains challenging, besides the various ongoing research and implementation actions on European, national and regional level. To overcome these hurdles, the International Consortium for Personalised Medicine (ICPerMed) is currently being initiated as a joint endeavour of the European Commission (EC) and more than 20 Member States. ICPerMed aims at aligning present as well as future efforts in all areas of PM by fostering international coordination of research and innovation funding. For this purpose, ICPerMed will develop and operate a European platform for collaboration between funders of PM research. It will promote an interdisciplinary approach to PM and generate policies, best practices, guidelines, and standards. ICPerMed secretariat will substantially contribute to the success of ICPerMed by efficiently coordinating all consortium activities, by implementing an effective dissemination plan and by assisting in the development of a sustainability strategy. By monitoring ongoing research funding activities in Europe and beyond, the secretariat will serve as the basis for evidence-informed allocation of research funding. ICPerMed secretariat will provide professional support in organising ICPerMed events and the meetings of ICPerMed bodies. In addition, ICPerMed secretariat will guide the dialogue with relevant stakeholders and initiatives. The organisational and logistical support of a secretariat will maximise the unique and long-term impact of ICPerMed by strengthening Europe's leading role in the successful implementation of PM in the global context.

The potential of personalised medicine (PM) is to improve prevention, diagnosis and treatment of diseases by taking into account individuals' genotypes and phenotypes as well as other biomedical, life style and environmental data. However, with some exceptions in cancer and rare diseases, PM has not yet arrived in clinical practice due to fragmentation, undefined legal and regulatory frameworks and its unclear economic value. To overcome these hurdles, ICPerMed was founded to initiate and support communication and exchange on PM research, funding and implementation. ICPerMed provides a platform to identify the requirements for a suitable framework in terms of infrastructures, resources and regulatory procedures to foster the development and implementation of PM. The ICPerMed Secretariat will continue to substantially contribute to the success of ICPerMed by efficiently coordinating all consortium activities. This includes supporting the ICPerMed governance and working groups as well as organising ICPerMed internal meetings and thematic events. A further important task of the ICPerMed Secretariat will be the implementation of an effective dissemination plan and the assistance in the development of a sustainability strategy. By monitoring ongoing research funding activities and collecting “Best Practice Examples”, the secretariat will provide the basis for evidence informed allocation of research funding and regulatory framework and standard development. The ICPerMed Secretariat will guide the dialogue with relevant stakeholders and initiatives. It will support training measures in PM in order to facilitate implementation of PM into practice. The organisational and logistical support of a secretariat will maximise the unique and long-term impact of ICPerMed by strengthening Europe's leading role in the successful implementation of PM in the global context.

The overall objective of CASA is a consolidated common agricultural and wider bioeconomy research agenda within the European Research Area. The common research agenda will be jointly shared by Member States of the European Union and Associated Countries. It will improve the alignment and interoperability of the respective national research programme(s). This will be achieved through enhanced cooperation, coordination and information exchange between the Member States, Associated Countries and the European Commission. This includes increasing the opportunities for Member States and Associated Countries to engage in the aforementioned activities. The conduit for this will be the Standing Committee of Agricultural Research (SCAR) and the various SCAR working groups, through which all Member States and Associated Countries are brought together with a view to fostering cooperation, coordination and information exchange, as well as streamlining research policy, in the bioeconomy and closely related fields. The overarching aim of CASA will be achieved through the accomplishment of the following four specific objectives: 1. Increased and broadened participation, interaction and collaboration of Member States and Associated Countries 2. Improved quality of outputs and outcomes of the Standing Committee of Agricultural Research creating added value for greater impact 3. Strengthening the production of more strategic policy advice by the Standing Committee of Agricultural Research based on the increased, deepened and broadened participation facilitated by CASA 4. Improve overall organisation, communication and dissemination of SCAR activities, outputs and outcomes for greater impact

At the highest political levels antimicrobial resistance (AMR) is recognised as major threat to the health of citizens and societies, food security and development as it threatens the effective prevention and treatment of infections and thus the attainment of the Sustainable Development Goals. Global cooperation to address AMR with a one health approach is needed to tackle increasing levels of AMR in bacteria, fungi, viruses and parasites, which present a major threat to human, animal, plant and environmental health. DESIGN OH AMR aims to promote a one health response to link the multisectoral AMR research and innovation landscape. The DESIGN OH AMR will lay the preparatory groundwork of the candidate European co-funded partnership on OH AMR by addressing the ?European One Health Action Plan against AMR?. It will develop the strategic basis for the OH AMR partnership through engaging with, and building on, networks of research funders, policy makers, relevant agencies, European partnerships under the Horizon 2020 Framework Programme, and authorities to strengthen coordination and collaboration among different fields of research and innovation with relevance to AMR.